Cargando…
The prognosis after contraindicated surgery of NSCLC patients with malignant pleural effusion (M1a) may be better than expected
Although non-small cell lung cancer (NSCLC) with malignant pleural effusion (M1a) is generally contraindicated for surgery, several reports have demonstrated favorable prognosis. This study aimed to describe the results of surgical intervention in this disease. In this retrospective study, we evalua...
Autores principales: | Ren, Yijiu, Dai, Chenyang, Shen, Jianfei, Liu, Yang, Xie, Dong, Zheng, Hui, He, Jiaxi, Liang, Wenhua, Jiang, Gening, Fei, Ke, Yang, Ping, He, Jianxing, Chen, Chang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042020/ https://www.ncbi.nlm.nih.gov/pubmed/27057627 http://dx.doi.org/10.18632/oncotarget.8566 |
Ejemplares similares
-
Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion
por: Takeuchi, Eiji, et al.
Publicado: (2021) -
Pleural MAC30 as a prognostic marker in NSCLC with malignant pleural effusion
por: Shan, Yi, et al.
Publicado: (2017) -
Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021) -
The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions
por: Wang, Jinlin, et al.
Publicado: (2017) -
Detection and Significance of Cell-Free DNA Mutation in Pleural Effusion in Patients with Advanced NSCLC
por: Qiao, Man, et al.
Publicado: (2022)